These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17602896)

  • 1. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
    Bicek A; Turel I; Kanduser M; Miklavcic D
    Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
    Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
    Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
    J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
    Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
    Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M; Baracco S; Cassino C; Zanello P; Osella D
    Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
    Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
    Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.
    Sava G; Gagliardi R; Bergamo A; Alessio E; Mestroni G
    Anticancer Res; 1999; 19(2A):969-72. PubMed ID: 10368640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
    Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
    Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruthenium complexes can target determinants of tumour malignancy.
    Bergamo A; Sava G
    Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
    Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
    Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
    Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
    Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
    Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
    Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
    Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
    Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.
    Frausin F; Cocchietto M; Bergamo A; Scarcia V; Furlani A; Sava G
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):405-11. PubMed ID: 12439599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
    Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
    Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases.
    Ravera M; Baracco S; Cassino C; Colangelo D; Bagni G; Sava G; Osella D
    J Inorg Biochem; 2004 Jun; 98(6):984-90. PubMed ID: 15149805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
    Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
    J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.